Revvity Inc (RVTY)

Currency in USD
85.90
-2.78(-3.13%)
Closed·
After Hours
85.900.00(0.00%)
·
RVTY Scorecard
Full Analysis
Has a perfect Piotroski Score of 9
Trading near 52-week Low
RVTY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
85.1288.66
52 wk Range
85.12129.50
Key Statistics
Prev. Close
85.9
Open
88.47
Day's Range
85.12-88.66
52 wk Range
85.12-129.5
Volume
1.22M
Average Volume (3m)
1.28M
1-Year Change
-28.43%
Book Value / Share
64.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RVTY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
116.81
Upside
+35.99%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

Revvity Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Revvity Inc Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Revvity Inc Earnings Call Summary for Q2/2025

  • Q2 EPS of $1.18 beat $1.14 forecast; revenue of $720M exceeded $710.39M estimate; stock fell 9.33% premarket
  • Full-year EPS guidance lowered to $4.85-$4.95; organic growth of 2-4% expected; focus on margin expansion and cost management
  • $450M stock repurchase reduced shares by 4%; free cash flow at $115M with 83% conversion rate of adjusted net income
  • China diagnostics market faces challenges due to policy changes; uncertainty in academic/government sectors and NIH funding
  • Reproductive health segment projected for high single-digit growth by Q4; new IDS I-20 analytical platform launched
Last Updated: 28/07/2025, 14:14
Read Full Transcript

Compare RVTY to Peers and Sector

Metrics to compare
RVTY
Peers
Sector
Relationship
P/E Ratio
36.3x29.3x−0.5x
PEG Ratio
0.500.060.00
Price/Book
1.3x3.1x2.6x
Price / LTM Sales
3.6x3.8x3.3x
Upside (Analyst Target)
33.9%39.5%43.5%
Fair Value Upside
Unlock0.3%6.9%Unlock

Analyst Ratings

12 Buy
6 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 116.81
(+35.99% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.31%
Dividend Yield
0.33%
Industry Median 1.33%
Annualised payout
0.28
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Jul 28, 2025
EPS / Forecast
1.18 / 1.14
Revenue / Forecast
720.00M / 710.39M
EPS Revisions
Last 90 days

RVTY Income Statement

People Also Watch

25.21
CNC
-2.63%
152.31
MOH
-1.89%
134.04
FI
-0.18%
276.30
ELV
-0.04%
136.91
ALGN
-1.97%

FAQ

What Stock Exchange Does Revvity Trade On?

Revvity is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Revvity?

The stock symbol for Revvity is "RVTY."

What Is the Revvity Market Cap?

As of today, Revvity market cap is 10.13B.

What Is Revvity's Earnings Per Share (TTM)?

The Revvity EPS (TTM) is 2.31.

When Is the Next Revvity Earnings Date?

Revvity will release its next earnings report on 03 Nov 2025.

From a Technical Analysis Perspective, Is RVTY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Revvity Stock Split?

Revvity has split 4 times.

How Many Employees Does Revvity Have?

Revvity has 11000 employees.

What is the current trading status of Revvity (RVTY)?

As of 07 Aug 2025, Revvity (RVTY) is trading at a price of 85.90, with a previous close of 85.90. The stock has fluctuated within a day range of 85.12 to 88.66, while its 52-week range spans from 85.12 to 129.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.